Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
May 2025
-
Featured News
test news
-
Featured News
Automatic push of the feature news
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras lacinia et tellus sit amet porttitor. Proin ante justo, pulvinar nec neque quis, gravida molestie ligula. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed eget elit fermentum orci eleifend varius. Nunc molestie ornare magna at finibus. Donec quis tempus elit. Suspendisse gravida mi non ultricies laoreet. Sed aliquet mi eu dui finibus sagittis. Fusce efficitur eros nec sem auctor, in facilisis sapien consequat. Donec luctus gravida turpis, vel facilisis est lacinia at. Mauris ultricies volutpat lobortis. Suspendisse facilisis, risus convallis suscipit maximus, lectus ligula tincidunt augue, nec placerat purus tellus in mi. Maecenas ut dui non ex feugiat interdum. In egestas pulvinar eros in rhoncus. Aliquam in lacus orci. Sed auctor, purus in porta interdum, sem justo dignissim lorem, at placerat ligula quam ultrices felis.
Phasellus a commodo nisl, vel scelerisque mi. Donec volutpat sapien nisl, eu pulvinar dui placerat ac. Nullam aliquam congue turpis, vel placerat eros. Curabitur ut dolor imperdiet elit placerat blandit. Nullam mi metus, faucibus ac tellus et, elementum placerat erat. Sed ullamcorper lacinia pellentesque. Mauris eget pulvinar sapien. Mauris vitae lectus ac lorem feugiat blandit eu ac purus. Quisque magna elit, suscipit quis mattis ac, feugiat nec mauris. Aliquam mattis diam sit amet ex hendrerit, sit amet aliquet felis molestie. Duis feugiat risus et pellentesque finibus. Cras sollicitudin dolor nec pharetra posuere. Aenean nunc mi, accumsan sed tortor et, maximus tincidunt quam. Duis volutpat nibh in velit rhoncus scelerisque. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Vestibulum ac consequat orci.
-
Featured News
Content sync auto push and pull
March 2025
-
Press Release
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of NovartisKaren Hale to drive the next phase of… -
Key Release
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI)… -
Press Release
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients… -
Story Patient Perspectives
Marc’s story: Raising awareness of elevated Lp(a) in cardiovascular disease
-
Press Release
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Phase III study showed sustained proteinuria reduction at one year with favorable safety1Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause… -
Press Release
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
Treatment with investigational OAV101 IT led to statistically significant 2.39-point improvement on the HFMSE vs. 0.51 points in sham control armSafety findings were consistent in both treatment-… -
Press Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
Shareholders approved 28th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹ Shareholders elected Giovanni Caforio as new member and Chair of the Board… -
Press Release
Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut
Die Aktionärinnen und Aktionäre genehmigten die 28. Dividendenerhöhung in Folge. Für 2024 wird die Dividende auf CHF 3.50 (+6,1%) je Aktie erhöht, was einer Rendite von 3,5% entspricht1Die…